CoChat

Discovery of the Potent and Selective M1 PAM-Agonist N-[(3 R,4 S)-3-Hydroxytetrahydro-2 H-pyran-4-yl]-5-methyl-4-[4-(1,3-thiazol-4-yl)benzyl]pyridine-2-carboxamide (PF-06767832): Evaluation of Efficacy and Cholinergic Side Effects

Open access
Davoren, Jennifer E., Lee, Che-Wah, Garnsey, Michelle, Brodney, Michael A., Cordes, Jason, Dlugolenski, Keith, Edgerton, Jeremy R., Harris, Anthony R., Helal, Christopher J., Jenkinson, Stephen, Kauffman, Gregory W., Kenakin, Terrence P., Lazzaro, John T., Lotarski, Susan M., Mao, Yuxia, Nason, Deane M., Northcott, Carrie, Nottebaum, Lisa, O’Neil, Steven V., Pettersen, Betty, Popiolek, Michael, Reinhart, Veronica, Salomon-Ferrer, Romelia, Steyn, Stefanus J., Webb, Damien, Zhang, Lei, Grimwood, Sarah · 2016 · Journal of Medicinal Chemistry
Cited by 85

The DOI matches its Crossref record.

Abstract

It is hypothesized that selective muscarinic M1 subtype activation could be a strategy to provide cognitive benefits to schizophrenia and Alzheimer's disease patients while minimizing the cholinergic side effects observed with nonselective muscarinic orthosteric agonists. Selective activation of M1 with a positive allosteric modulator (PAM) has emerged as a new approach to achieve selective M1 activation. This manuscript describes the development of a series of M1-selective pyridone and pyridine amides and their key pharmacophores. Compound 38 (PF-06767832) is a high quality M1 selective PAM that has well-aligned physicochemical properties, good brain penetration and pharmacokinetic properties. Extensive safety profiling suggested that despite being devoid of mAChR M2/M3 subtype activity, compound 38 still carries gastrointestinal and cardiovascular side effects. These data provide strong evidence that M1 activation contributes to the cholinergic liabilities that were previously attributed to activation of the M2 and M3 receptors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.6b00544

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 85

Metadata

Authors
Davoren, J. E., Lee, C.-W., Garnsey, M., Brodney, M. A., Cordes, J., Dlugolenski, K., Edgerton, J. R., Harris, A. R., Helal, C. J., Jenkinson, S., Kauffman, G. W., Kenakin, T. P., Lazzaro, J. T., Lotarski, S. M., Mao, Y., Nason, D. M., Northcott, C., Nottebaum, L., O’Neil, S. V., Pettersen, B., Popiolek, M., Reinhart, V., Salomon-Ferrer, R., Steyn, S. J., Webb, D., Zhang, L., & Grimwood, S.
Venue
Journal of Medicinal Chemistry
Published
2016-07-01
Volume
59
Issue
13
Pages
6313-6328
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W2414103203
Cited by
85
References
0
FWCI
6.47
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Discovery of the Potent and Selective M1 PAM-Agonist N-[(3 R,4 S)-3-Hydroxytetrahydro-2 H-pyran-4-yl]-5-methyl-4-[4-(1,3-thiazol-4-yl)benzyl]pyridine-2-carboxamide (PF-06767832): Evaluation of Efficacy and Cholinergic Side Effects. https://app.cochat.ai/papers/10.1021/acs.jmedchem.6b00544
The paper
Davoren, J. E., Lee, C.-W., Garnsey, M., Brodney, M. A., Cordes, J., Dlugolenski, K., Edgerton, J. R., Harris, A. R., Helal, C. J., Jenkinson, S., Kauffman, G. W., Kenakin, T. P., Lazzaro, J. T., Lotarski, S. M., Mao, Y., Nason, D. M., Northcott, C., Nottebaum, L., O’Neil, S. V., . . . Grimwood, S. (2016). Discovery of the Potent and Selective M1 PAM-Agonist N-[(3 R,4 S)-3-Hydroxytetrahydro-2 H-pyran-4-yl]-5-methyl-4-[4-(1,3-thiazol-4-yl)benzyl]pyridine-2-carboxamide (PF-06767832): Evaluation of Efficacy and Cholinergic Side Effects. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6b00544

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.